Trim 2% (1/4 of Position)
CSL Ltd (CSL)
*** GENERAL ADVICE ONLY ***
Description
Industry: Biotechnology
CSL Limited is an international biopharmaceutical company based in Melbourne, Australia, founded in 1916. It operates through three segments: CSL Behring (plasma products, gene therapies, recombinants), CSL Seqirus (influenza products and pandemic services for governments), and CSL Vifor (therapies for iron deficiency and nephrology). The company also licenses its intellectual property and has a presence in countries like the US, Germany, the UK, Switzerland, and China.
Metrics
Date: 06/12/2023
Market Cap: $116.61B
PE: 34.20
Yield: 0.99%
Trade
Allocation: Trim 2% Entry: $240 Exit: $267 Profit: 11.25%
Catalyst
The CSL position that we put on initially is now 10% in the money. We are looking to trim 2% or 1/4 of our position to take a profit.
ORIGINAL - ADD 2%
CSL Ltd (CSL)
*** GENERAL ADVICE ONLY ***
Description
Industry: Biotechnology
CSL Limited is an international biopharmaceutical company based in Melbourne, Australia, founded in 1916. It operates through three segments: CSL Behring (plasma products, gene therapies, recombinants), CSL Seqirus (influenza products and pandemic services for governments), and CSL Vifor (therapies for iron deficiency and nephrology). The company also licenses its intellectual property and has a presence in countries like the US, Germany, the UK, Switzerland, and China.
Metrics
Date: 16/10/2023
Market Cap: $116.61B
PE: 34.20
Yield: 0.99%
Trade
Allocation: Add 2-4% Entry: <$242 Target: $329 Stop: $204
Catalyst
The main business of CSL is blood plasma, which shouldn’t be affected directly by the GLP-1. The recent acquisition of Vifor with its focus on kidney disease and obesity, may be affected, although a very solid pipeline of new products in the works are focused in areas GLP-1 drug will have little bearing on .
CSL is also very close to trial results for a heart attack drug CSL112, a key pipeline product for CSL. Base case assumptions imply a valuation of around $30/share.
Disclaimer: The recommendation given is general advice only. It does not take into account your personal objectives, financial situation, or specific needs. This information should not be your sole resource when making such decisions. We strongly recommend you to seek the advice of financial, taxation, and legal professionals before finalising any investment decisions.